Developer docs
API playgroundTry for free, no card

Search company profiles

Sermonix Pharmaceuticals

Full company profile

uuid00026y1

Namestring
Sermonix Pharmaceuticals
Legal namestring
Sermonix Pharmaceuticals
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Sermonix Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in late 2014 by David Portman, MD, and headquartered at 250 East Broad Street in Columbus, Ohio. The company develops female-specific oncology products, with its entire pipeline centered on lasofoxifene, a next-generation nonsteroidal selective estrogen receptor modulator (SERM) originally developed by Pfizer and later returned to Ligand Pharmaceuticals before Sermonix acquired global rights and pivoted the asset into ESR1-mutated metastatic breast cancer based on discoveries at Duke University. Lasofoxifene is an oral once-daily therapy that functions as an ESR1 antagonist, demonstrating anti-tumor activity as monotherapy and in combination with CDK4/6 inhibitors, with prior non-oncology data on more than 15,000 postmenopausal women supporting its tissue-selective profile and beneficial effects on vaginal and bone health.

The company's clinical program comprises ELAINE-1 (Phase 2 monotherapy vs fulvestrant), ELAINE-2 (Phase 2 combination with abemaciclib showing approximately 13 months median PFS and 56% ORR), ELAINE-3 (global Phase 3 registrational trial in 400 patients, more than 50% enrolled as of January 2026 with top-line data expected mid-2027), and an I-SPY 2 Endocrine Optimization Platform arm in neoadjuvant early-stage HR+/HER2- breast cancer. Prospective ESR1 mutation screening uses Guardant Health's Guardant360 CDx liquid biopsy, and enrollment leverages Tempus's TIME Trial Network just-in-time model. Sermonix supplements clinical work with the EQUALS patient-reported outcomes program and patient advocacy partnerships with METAvivor, FORCE, and the Chrysalis Initiative.

Sermonix operates without a traditional commercial sales motion today. It is pre-revenue and funds operations through equity financing (approximately $67.55 million disclosed across 2016, 2019, and 2021 rounds led by WILD Family Office and Perceptive Xontogeny Ventures Fund II). Its go-to-market model historically relied on KOL engagement at major oncology conferences (ASCO, ESMO, SABCS) and peer-reviewed publication. In December 2025, Sermonix licensed global development and commercialization rights (excluding Asia and certain Middle Eastern countries) to Athira Pharma, now rebranded as LeonaBio, for approximately $34.9 million in equity, $16.8 million in third-party payments, monthly payments of $75,000, and up to $100 million in milestones, while Henlius Biotech retains exclusive China rights under a separate January 2024 collaboration that produced Chinese IND approval in June 2024.

Short descriptiontext

Sermonix Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing lasofoxifene, an oral next-generation SERM, for ESR1-mutated ER+/HER2- metastatic breast cancer, with global Phase 3 ELAINE-3 enrollment underway and China rights licensed to Henlius Biotech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersColumbus, United States
HQ citystring
Columbus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
selective estrogen receptor modulators, metastatic breast cancer therapy, clinical stage biopharmaceutical, endocrine therapy oncology, female specific oncology
Industry4 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAKAFAJ
Breast Oncology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Commercialization (Future)
TypeOne Time License
Description

Sermonix Pharmaceuticals is a privately held clinical-stage biopharmaceutical company that does not currently generate revenue. The company is focused on developing and commercializing lasofoxifene for the treatment of metastatic breast cancer. Upon successful completion of clinical trials and regulatory approval, the company expects to commercialize its lead product candidate through traditional pharmaceutical sales channels.

sermonixpharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sermonix Pharmaceuticals is developing lasofoxifene, an investigational oral next-generation selective estrogen receptor modulator (SERM), for the treatment of estrogen receptor-positive (ER+)/HER2- metastatic breast cancer in patients with ESR1 mutations who have progressed on aromatase inhibitor and CDK4/6 inhibitor therapy. The drug is being advanced through the ELAINE clinical trial program (ELAINE-1 Phase 2 monotherapy vs fulvestrant, ELAINE-2 Phase 2 combination with abemaciclib, and ELAINE-3 Phase 3 registrational combination study) supported by Guardant360 CDx liquid biopsy companion diagnostics and Tempus TIME Trial Network enrollment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Median PFS of 6.04 months for lasofoxifene vs. 4.04 months for fulvestrant (P=0.138) in ELAINE-1
+5 more records
Product overview1 text field

Sermonix Pharmaceuticals is a privately held biotechnology company focused on the development of female-specific oncology products. The company's core product is lasofoxifene, a next-generation selective estrogen receptor modulator (SERM) in Phase 3 clinical development for treating metastatic breast cancer patients with ESR1 mutations. The product portfolio includes the ELAINE clinical trial program (ELAINE-1, ELAINE-2, ELAINE-3) evaluating lasofoxifene as monotherapy and in combination with CDK4/6 inhibitor abemaciclib, supplemented by the EQUALS patient quality-of-life survey program. The company also participates in the I-SPY 2 neoadjuvant study and has strategic collaborations with Henlius Biotech (China) and Regor for global development and target discovery.

Product and service2 records
1Lasofoxifene
CategoryOncology Therapeutics / Selective Estrogen Receptor Modulator
Description

Investigational oral next-generation selective estrogen receptor modulator (SERM) being developed for the treatment of estrogen receptor-positive (ER+)/HER2- metastatic breast cancer with ESR1 mutations. Demonstrates robust target engagement as an ESR1 antagonist in the breast, with anti-tumor activity as monotherapy and in combination with CDK4/6 inhibitors (abemaciclib). Has unique tissue selectivity with beneficial effects on vaginal and bone health versus current endocrine therapies.

2ELAINE Clinical Trial Program (ELAINE-1, ELAINE-2, ELAINE-3)
CategoryClinical Development Program / Oncology Trials
Description

Series of open-label, randomized, multicenter clinical trials evaluating lasofoxifene in patients with ESR1-mutated metastatic breast cancer. ELAINE-1 compares lasofoxifene monotherapy vs fulvestrant; ELAINE-2 evaluates lasofoxifene plus abemaciclib combination; ELAINE-3 is the registrational Phase 3 study of lasofoxifene plus abemaciclib vs fulvestrant plus abemaciclib. Trials are conducted across the U.S., Europe, Israel, Canada, and Asia-Pacific with Guardant360 CDx companion diagnostic screening.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-03-27
Description

Strategic collaboration to optimize Regor's proprietary rCARD platform for identification of novel targets and therapeutics. The partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer by leveraging Regor's innovative discovery platform alongside Sermonix's expertise in female-specific oncology.

2Henlius Biotech (Shanghai Henlius Biotech)
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-01-10
Description

Strategic collaboration and exclusive license agreements for lasofoxifene. Henlius acquired exclusive rights to develop and commercialize lasofoxifene in China, expanding Sermonix's global development footprint. The partnership allows Henlius to expand its portfolio with license of exclusive China rights for this novel endocrine therapy. Henlius subsequently received Chinese IND approval for lasofoxifene.

sermonixpharma.com
3Tempus
Strategic tierKeyTypeTechnology or IntegrationAnnounced on2023-06-26
Description

Collaboration using Tempus TIME Trial Network for patient enrollment in ELAINE-2 and ELAINE-3 studies. Sermonix enrolled 45% of ELAINE-2 patients through this just-in-time enrollment model, which rapidly opens trial sites closer to patient homes after eligibility identification. TIME Trial sites reduced contract execution time from 200.5 days to 7.6 days on average.

sermonixpharma.com
Strategic tierKeyTypeTechnology or IntegrationAnnounced on2023-03-09
Description

Companion diagnostic partnership for ESR1 mutation detection using Guardant360 CDx liquid biopsy in ELAINE-3 trial. Guardant360 CDx is the first FDA-approved blood test for comprehensive genomic profiling for all solid tumors. This partnership enables prospective screening of subjects for ESR1 mutations using NGS-based liquid biopsy technology.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2023-02-13
Description

Collaboration for I-SPY 2 Endocrine Optimization Pilot Protocol (EOP) evaluating lasofoxifene as neoadjuvant endocrine therapy in HR+/HER2- breast cancer. Quantum Leap serves as trial sponsor and manages all study operations. Sermonix supplies lasofoxifene and provides financial support. The I-SPY program includes 41 major U.S. cancer research centers.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Global license agreement for lasofoxifene development and commercialization. Ligand originally developed lasofoxifene; Pfizer had developed it and returned rights to Ligand after 2009 FDA complete response letter. Sermonix subsequently in-licensed the asset and pivoted it to oncology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive rights to develop and commercialize lasofoxifene for ESR1 mutations. Duke University researchers discovered lasofoxifene's novel activity in ESR1 mutations, which forms the basis of Sermonix's precision medicine approach targeting this specific patient population.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Clinical trial collaboration and drug supply agreement. Eli Lilly provides abemaciclib (Verzenio) for the ELAINE-3 Phase 3 study. Sermonix uses 150 mg abemaciclib twice daily in combination with lasofoxifene in the registrational trial.

9METAvivor Research and Support
Strategic tierSupportingTypeGTM or Marketing Partner
Description

Patient advocacy partnership supporting the EQUALS survey program. METAvivor helped ensure diverse patient participation in surveys examining quality of life and genomic knowledge among metastatic breast cancer patients.

sermonixpharma.com
Strategic tierSupportingTypeGTM or Marketing Partner
Description

Patient advocacy partnership supporting diversity in clinical research and patient education. Partnered with Sermonix for the EQUALS survey program to reach ethnically diverse patient populations.

Strategic tierSupportingTypeGTM or Marketing Partner
Description

Patient advocacy partnership supporting metastatic breast cancer awareness and education. Partnered with Sermonix for EQUALS survey program examining patient knowledge of genomic testing and quality of life concerns.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Radius developed and Menarini commercializes elacestrant (Orserdu), the first FDA-approved oral SERD for ER+/HER2- metastatic breast cancer with ESR1 mutations — the most direct competitor to Sermonix's lasofoxifene in the same ESR1-mutated patient population.

TypeDirect peer
Description

Clinical-stage oncology company developing palazestrant, an oral SERD for ER+/HER2- metastatic breast cancer, including in ESR1-mutated settings. Directly competes with lasofoxifene on mechanism (oral endocrine therapy in post-CDK4/6i patients) and indication.

TypeDirect peer
Description

Developing vepdegestrant, an oral PROTAC estrogen receptor degrader in partnership with Pfizer for ER+/HER2- metastatic breast cancer. Competes with lasofoxifene in next-generation oral endocrine therapy for ESR1-mutated and broader ER+ populations.

TypeBroad incumbent
Description

Markets fulvestrant (Faslodex) — the comparator in Sermonix's ELAINE-1 and ELAINE-3 trials — and is developing camizestrant, a next-generation oral SERD. Broad incumbent in breast cancer endocrine therapy with full-scale commercialization.

TypeBroad incumbent
Description

Develops giredestrant, an oral SERD in Phase III for ER+ metastatic breast cancer. As a broad oncology incumbent with established breast cancer franchise, competes directly with lasofoxifene's positioning in ESR1-mutated and broader ER+ populations.

TypeBroad incumbent
Description

Markets Verzenio (abemaciclib), the CDK4/6 inhibitor used in Sermonix's ELAINE-2 and ELAINE-3 combination regimens. Strategic drug-supply partner and a broader breast cancer endocrine therapy competitor.

TypeBroad incumbent
Description

Originally developed lasofoxifene (returned to Ligand after 2009 CRL) and markets Ibrance (palbociclib), a leading CDK4/6 inhibitor used in ER+ metastatic breast cancer. Both a legacy developer of Sermonix's core asset and a broad competitive incumbent.

TypeOthers
Description

Original licensor of lasofoxifene to Sermonix and previously to Pfizer. Comparable as a small-molecule licensing platform with specialty pharmaceutical exposure, including in women's health (e.g., bazedoxifene via Duavee).

TypeEmerging player
Description

Recently rebranded from Athira Pharma (formerly CNS-focused) to focus on oncology after licensing global ex-Asia lasofoxifene rights from Sermonix in December 2025. Comparable as a clinical-stage oncology company now anchored by the same asset Sermonix developed.

TypeOthers
Description

Sermonix's companion diagnostic partner, providing Guardant360 CDx — the first FDA-approved liquid biopsy for comprehensive tumor profiling — for ESR1 mutation screening in ELAINE-3. Comparable as an enabler of precision patient identification in Sermonix's clinical and (future) commercial workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sermonix Pharmaceuticals

Oncology Therapeuticssermonixpharma.com

Sermonix Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing lasofoxifene, an oral next-generation SERM, for ESR1-mutated ER+/HER2- metastatic breast cancer, with global Phase 3 ELAINE-3 enrollment underway and China rights licensed to Henlius Biotech.

What Sermonix Pharmaceuticals does

Sermonix Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in late 2014 by David Portman, MD, and headquartered at 250 East Broad Street in Columbus, Ohio. The company develops female-specific oncology products, with its entire pipeline centered on lasofoxifene, a next-generation nonsteroidal selective estrogen receptor modulator (SERM) originally developed by Pfizer and later returned to Ligand Pharmaceuticals before Sermonix acquired global rights and pivoted the asset into ESR1-mutated metastatic breast cancer based on discoveries at Duke University. Lasofoxifene is an oral once-daily therapy that functions as an ESR1 antagonist, demonstrating anti-tumor activity as monotherapy and in combination with CDK4/6 inhibitors, with prior non-oncology data on more than 15,000 postmenopausal women supporting its tissue-selective profile and beneficial effects on vaginal and bone health.

The company's clinical program comprises ELAINE-1 (Phase 2 monotherapy vs fulvestrant), ELAINE-2 (Phase 2 combination with abemaciclib showing approximately 13 months median PFS and 56% ORR), ELAINE-3 (global Phase 3 registrational trial in 400 patients, more than 50% enrolled as of January 2026 with top-line data expected mid-2027), and an I-SPY 2 Endocrine Optimization Platform arm in neoadjuvant early-stage HR+/HER2- breast cancer. Prospective ESR1 mutation screening uses Guardant Health's Guardant360 CDx liquid biopsy, and enrollment leverages Tempus's TIME Trial Network just-in-time model. Sermonix supplements clinical work with the EQUALS patient-reported outcomes program and patient advocacy partnerships with METAvivor, FORCE, and the Chrysalis Initiative.

Sermonix operates without a traditional commercial sales motion today. It is pre-revenue and funds operations through equity financing (approximately $67.55 million disclosed across 2016, 2019, and 2021 rounds led by WILD Family Office and Perceptive Xontogeny Ventures Fund II). Its go-to-market model historically relied on KOL engagement at major oncology conferences (ASCO, ESMO, SABCS) and peer-reviewed publication. In December 2025, Sermonix licensed global development and commercialization rights (excluding Asia and certain Middle Eastern countries) to Athira Pharma, now rebranded as LeonaBio, for approximately $34.9 million in equity, $16.8 million in third-party payments, monthly payments of $75,000, and up to $100 million in milestones, while Henlius Biotech retains exclusive China rights under a separate January 2024 collaboration that produced Chinese IND approval in June 2024.

Sermonix Pharmaceuticals firmographics

Firmographics
Name
Sermonix Pharmaceuticals
Legal name
Sermonix Pharmaceuticals
Website
https://sermonixpharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Sermonix Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing lasofoxifene, an oral next-generation SERM, for ESR1-mutated ER+/HER2- metastatic breast cancer, with global Phase 3 ELAINE-3 enrollment underway and China rights licensed to Henlius Biotech.
Ownership category
akta.pro rank

Sermonix Pharmaceuticals industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAKAFAJ
Breast Oncology

Keywords

  • Selective estrogen receptor modulators
  • Metastatic breast cancer therapy
  • Clinical stage biopharmaceutical
  • Endocrine therapy oncology
  • Female specific oncology

Where Sermonix Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Columbus
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sermonix Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Commercialization (Future): Sermonix Pharmaceuticals is a privately held clinical-stage biopharmaceutical company that does not currently generate revenue. The company is focused on developing and commercializing lasofoxifene for the treatment of metastatic breast cancer. Upon successful completion of clinical trials and regulatory approval, the company expects to commercialize its lead product candidate through traditional pharmaceutical sales channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Sermonix Pharmaceuticals product offering

Product offering

Core offering

Sermonix Pharmaceuticals is developing lasofoxifene, an investigational oral next-generation selective estrogen receptor modulator (SERM), for the treatment of estrogen receptor-positive (ER+)/HER2- metastatic breast cancer in patients with ESR1 mutations who have progressed on aromatase inhibitor and CDK4/6 inhibitor therapy. The drug is being advanced through the ELAINE clinical trial program (ELAINE-1 Phase 2 monotherapy vs fulvestrant, ELAINE-2 Phase 2 combination with abemaciclib, and ELAINE-3 Phase 3 registrational combination study) supported by Guardant360 CDx liquid biopsy companion diagnostics and Tempus TIME Trial Network enrollment.

Product overview

Sermonix Pharmaceuticals is a privately held biotechnology company focused on the development of female-specific oncology products. The company's core product is lasofoxifene, a next-generation selective estrogen receptor modulator (SERM) in Phase 3 clinical development for treating metastatic breast cancer patients with ESR1 mutations. The product portfolio includes the ELAINE clinical trial program (ELAINE-1, ELAINE-2, ELAINE-3) evaluating lasofoxifene as monotherapy and in combination with CDK4/6 inhibitor abemaciclib, supplemented by the EQUALS patient quality-of-life survey program. The company also participates in the I-SPY 2 neoadjuvant study and has strategic collaborations with Henlius Biotech (China) and Regor for global development and target discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lasofoxifene Investigational oral next-generation selective estrogen receptor modulator (SERM) being developed for the treatment of estrogen receptor-positive (ER+)/HER2- metastatic breast cancer with ESR1 mutations. Demonstrates robust target engagement as an ESR1 antagonist in the breast, with anti-tumor activity as monotherapy and in combination with CDK4/6 inhibitors (abemaciclib). Has unique tissue selectivity with beneficial effects on vaginal and bone health versus current endocrine therapies.
  • ELAINE Clinical Trial Program (ELAINE-1, ELAINE-2, ELAINE-3) Series of open-label, randomized, multicenter clinical trials evaluating lasofoxifene in patients with ESR1-mutated metastatic breast cancer. ELAINE-1 compares lasofoxifene monotherapy vs fulvestrant; ELAINE-2 evaluates lasofoxifene plus abemaciclib combination; ELAINE-3 is the registrational Phase 3 study of lasofoxifene plus abemaciclib vs fulvestrant plus abemaciclib. Trials are conducted across the U.S., Europe, Israel, Canada, and Asia-Pacific with Guardant360 CDx companion diagnostic screening.

Quantifiable outcome

  • Median PFS of 6.04 months for lasofoxifene vs. 4.04 months for fulvestrant (P=0.138) in ELAINE-1
  • +5 more outcomes

Companies that use Sermonix Pharmaceuticals

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Sermonix Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Sermonix Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered supporting, key and core.

  • RegorsupportingStrategic or Co-development Partner · 27 March 2025Strategic collaboration to optimize Regor's proprietary rCARD platform for identification of novel targets and therapeutics. The partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer by leveraging Regor's innovative discovery platform alongside Sermonix's expertise in female-specific oncology.
  • Henlius Biotech (Shanghai Henlius Biotech)keyStrategic or Co-development Partner · 10 January 2024Strategic collaboration and exclusive license agreements for lasofoxifene. Henlius acquired exclusive rights to develop and commercialize lasofoxifene in China, expanding Sermonix's global development footprint. The partnership allows Henlius to expand its portfolio with license of exclusive China rights for this novel endocrine therapy. Henlius subsequently received Chinese IND approval for lasofoxifene.
  • TempuskeyTechnology or Integration · 26 June 2023Collaboration using Tempus TIME Trial Network for patient enrollment in ELAINE-2 and ELAINE-3 studies. Sermonix enrolled 45% of ELAINE-2 patients through this just-in-time enrollment model, which rapidly opens trial sites closer to patient homes after eligibility identification. TIME Trial sites reduced contract execution time from 200.5 days to 7.6 days on average.
  • Guardant HealthkeyTechnology or Integration · 9 March 2023Companion diagnostic partnership for ESR1 mutation detection using Guardant360 CDx liquid biopsy in ELAINE-3 trial. Guardant360 CDx is the first FDA-approved blood test for comprehensive genomic profiling for all solid tumors. This partnership enables prospective screening of subjects for ESR1 mutations using NGS-based liquid biopsy technology.
  • Quantum Leap Healthcare CollaborativekeyStrategic or Co-development Partner · 13 February 2023Collaboration for I-SPY 2 Endocrine Optimization Pilot Protocol (EOP) evaluating lasofoxifene as neoadjuvant endocrine therapy in HR+/HER2- breast cancer. Quantum Leap serves as trial sponsor and manages all study operations. Sermonix supplies lasofoxifene and provides financial support. The I-SPY program includes 41 major U.S. cancer research centers.
  • Ligand PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerGlobal license agreement for lasofoxifene development and commercialization. Ligand originally developed lasofoxifene; Pfizer had developed it and returned rights to Ligand after 2009 FDA complete response letter. Sermonix subsequently in-licensed the asset and pivoted it to oncology.
  • Duke UniversitycoreStrategic or Co-development PartnerExclusive rights to develop and commercialize lasofoxifene for ESR1 mutations. Duke University researchers discovered lasofoxifene's novel activity in ESR1 mutations, which forms the basis of Sermonix's precision medicine approach targeting this specific patient population.
  • Eli Lilly and CompanykeyStrategic or Co-development PartnerClinical trial collaboration and drug supply agreement. Eli Lilly provides abemaciclib (Verzenio) for the ELAINE-3 Phase 3 study. Sermonix uses 150 mg abemaciclib twice daily in combination with lasofoxifene in the registrational trial.
  • METAvivor Research and SupportsupportingGTM or Marketing PartnerPatient advocacy partnership supporting the EQUALS survey program. METAvivor helped ensure diverse patient participation in surveys examining quality of life and genomic knowledge among metastatic breast cancer patients.
  • The Chrysalis InitiativesupportingGTM or Marketing PartnerPatient advocacy partnership supporting diversity in clinical research and patient education. Partnered with Sermonix for the EQUALS survey program to reach ethnically diverse patient populations.
  • FORCE (Facing Our Risk of Cancer)supportingGTM or Marketing PartnerPatient advocacy partnership supporting metastatic breast cancer awareness and education. Partnered with Sermonix for EQUALS survey program examining patient knowledge of genomic testing and quality of life concerns.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Sermonix Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Radius Health (Menarini Group): Radius developed and Menarini commercializes elacestrant (Orserdu), the first FDA-approved oral SERD for ER+/HER2- metastatic breast cancer with ESR1 mutations — the most direct competitor to Sermonix's lasofoxifene in the same ESR1-mutated patient population.
  • Olema Oncology: Clinical-stage oncology company developing palazestrant, an oral SERD for ER+/HER2- metastatic breast cancer, including in ESR1-mutated settings. Directly competes with lasofoxifene on mechanism (oral endocrine therapy in post-CDK4/6i patients) and indication.
  • Arvinas: Developing vepdegestrant, an oral PROTAC estrogen receptor degrader in partnership with Pfizer for ER+/HER2- metastatic breast cancer. Competes with lasofoxifene in next-generation oral endocrine therapy for ESR1-mutated and broader ER+ populations.

Broad incumbents

  • AstraZeneca: Markets fulvestrant (Faslodex) — the comparator in Sermonix's ELAINE-1 and ELAINE-3 trials — and is developing camizestrant, a next-generation oral SERD. Broad incumbent in breast cancer endocrine therapy with full-scale commercialization.
  • Roche / Genentech: Develops giredestrant, an oral SERD in Phase III for ER+ metastatic breast cancer. As a broad oncology incumbent with established breast cancer franchise, competes directly with lasofoxifene's positioning in ESR1-mutated and broader ER+ populations.
  • Eli Lilly: Markets Verzenio (abemaciclib), the CDK4/6 inhibitor used in Sermonix's ELAINE-2 and ELAINE-3 combination regimens. Strategic drug-supply partner and a broader breast cancer endocrine therapy competitor.
  • Pfizer: Originally developed lasofoxifene (returned to Ligand after 2009 CRL) and markets Ibrance (palbociclib), a leading CDK4/6 inhibitor used in ER+ metastatic breast cancer. Both a legacy developer of Sermonix's core asset and a broad competitive incumbent.

Others

  • Ligand Pharmaceuticals: Original licensor of lasofoxifene to Sermonix and previously to Pfizer. Comparable as a small-molecule licensing platform with specialty pharmaceutical exposure, including in women's health (e.g., bazedoxifene via Duavee).
  • Guardant Health: Sermonix's companion diagnostic partner, providing Guardant360 CDx — the first FDA-approved liquid biopsy for comprehensive tumor profiling — for ESR1 mutation screening in ELAINE-3. Comparable as an enabler of precision patient identification in Sermonix's clinical and (future) commercial workflow.

Emerging players

  • LeonaBio (formerly Athira Pharma): Recently rebranded from Athira Pharma (formerly CNS-focused) to focus on oncology after licensing global ex-Asia lasofoxifene rights from Sermonix in December 2025. Comparable as a clinical-stage oncology company now anchored by the same asset Sermonix developed.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sermonix Pharmaceuticals social profiles

Digital presence

Sermonix Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sermonix Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Sermonix Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sermonix Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sermonix Pharmaceuticals

What does Sermonix Pharmaceuticals do?

Sermonix Pharmaceuticals is developing lasofoxifene, an investigational oral next-generation selective estrogen receptor modulator (SERM), for the treatment of estrogen receptor-positive (ER+)/HER2- metastatic breast cancer in patients with ESR1 mutations who have progressed on aromatase inhibitor and CDK4/6 inhibitor therapy. The drug is being advanced through the ELAINE clinical trial program (ELAINE-1 Phase 2 monotherapy vs fulvestrant, ELAINE-2 Phase 2 combination with abemaciclib, and ELAINE-3 Phase 3 registrational combination study) supported by Guardant360 CDx liquid biopsy companion diagnostics and Tempus TIME Trial Network enrollment.

Is Sermonix Pharmaceuticals a public or private company?

Sermonix Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sermonix Pharmaceuticals founded?

Sermonix Pharmaceuticals was founded in 2014. It employs 1 to 10 people.

Where is Sermonix Pharmaceuticals based?

Sermonix Pharmaceuticals is headquartered in Columbus, United States, in the North America region.

How does Sermonix Pharmaceuticals make money?

One revenue line is on record: drug Commercialization (Future).

Who are Sermonix Pharmaceuticals's main competitors?

Direct peers on record are Radius Health (Menarini Group), Olema Oncology and Arvinas. Broad incumbents are AstraZeneca, Roche / Genentech, Eli Lilly and Pfizer. Others are Ligand Pharmaceuticals and Guardant Health. LeonaBio (formerly Athira Pharma) is listed as an emerging player.

Does Sermonix Pharmaceuticals have an API?

No public API is recorded for Sermonix Pharmaceuticals.

What industry is Sermonix Pharmaceuticals in?

Sermonix Pharmaceuticals's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceLeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast CancerLeonaBio will present its lead drug lasofoxifene at DAVA Oncology's 4th Breast Cancer Summit in Hawaii, with presentations by Dr. Jessica Tao and Dr. David Portman. The company is on track to complete enrollment in the Phase 3 ELAINE-3 trial in 4Q 2026, with topline data expected in 2H 2027.GlobeNewswireESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsightThe market for ESR1-mutated metastatic breast cancer is expected to grow at a CAGR of 9.6% from 2026 to 2036, driven by the increasing prevalence of endocrine-resistant breast cancer and the development of new therapies like oral SERDs and targeted agents. Key companies such as Roche, AstraZeneca, Olema Pharmaceuticals, and Sermonix Pharmaceuticals are actively developing treatments, with recent FDA approvals supporting market expansion.BioSpaceLeonaBio Reports Full Year 2025 Financial Results and Provides Business UpdateLeonaBio, Inc. (formerly Athira Pharma) reported full year 2025 financial results, posting a net loss of $105.6 million compared to a net loss of $96.9 million in 2024, with cash position increasing to $88.3 million from $51.3 million. In December 2025, the company acquired an exclusive global license from Sermonix Pharmaceuticals for lasofoxifene, a Phase 3 selective estrogen receptor modulator for metastatic breast cancer with ESR1 mutations, alongside completing a $90 million private placement financing with warrants potentially providing up to an additional $146 million. The company is on track to complete enrollment of the Phase 3 ELAINE-3 clinical trial in Q4 2026 and expects to initiate a Phase 2 proof-of-concept study for ATH-1105 in ALS patients in H2 2026.Investing.comAthira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug By Investing.comAthira Pharma's stock surged 73.4% after acquiring global rights to develop and commercialize lasofoxifene, a late-stage breast cancer treatment in Phase 3 trials. The company secured an exclusive license from Sermonix Pharmaceuticals and announced a $90 million private placement financing, extending its financial runway into 2028.FierceBiotechAthira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer dataAthira Pharma has secured near-global rights to lasofoxifene, a phase 3 breast cancer drug candidate, in a deal with Sermonix Pharmaceuticals that involves issuing approximately $34.9 million in equity, $16.8 million in third-party payments, and monthly payments of $75,000 creditable against potential milestones totaling $100 million. Pfizer originally developed the selective estrogen receptor modulator and returned rights to Ligand Pharmaceuticals after a 2009 FDA complete response letter, with Sermonix later in-licensing the asset and pivoting it to oncology. Athira CEO Mark Litton projects the drug could achieve peak annual U.S. sales of approximately $1 billion, with phase 3 data expected in mid-2027, and the deal is accompanied by a $90 million private placement co-led by Perceptive Advisors.PR NewswireSermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and TherapeuticsSermonix Pharmaceuticals and Regor Therapeutics Group announced a strategic collaboration on March 24, 2025, to optimize Regor's proprietary rCARD™ computational drug discovery platform for identifying novel targets and therapeutics in metastatic breast cancer. The partnership combines Sermonix's Phase 3 asset lasofoxifene and clinical commercialization expertise with Regor's AI-driven small molecule discovery engine to develop treatments addressing efficacy, tolerability, and patient quality of life concerns. The companies aim to fill unmet needs in onco-sexuality, cardio-oncology, and bone health as breast cancer care evolves from a lethal to a chronic disease paradigm.GlobeNewswireSermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and TherapeuticsSermonix Pharmaceuticals and Regor Therapeutics announced a strategic collaboration to optimize Regor's rCARD platform for identifying novel breast cancer targets and therapeutics. Sermonix is developing lasofoxifene for ESR1-mutated ER+ HER2- metastatic breast cancer, with a Phase 3 trial underway. The partnership aims to address patient concerns in onco-sexuality, cardio oncology, and bone health.GlobeNewswireSermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and TherapeuticsSermonix Pharmaceuticals and Regor Therapeutics announced a strategic collaboration to optimize Regor's rCARD platform for identifying novel breast cancer targets and therapeutics. The partnership aims to combine Sermonix's Phase 3 lasofoxifene asset with Regor's drug discovery expertise. Sermonix is enrolling in its ELAINE-3 study comparing lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib.TempusOncology innovation: How emerging biotechs lead through RWD & AITempus is launching the Tempus Biotech Program, a new service integrating real-world data, AI, and Contract Research Organization capabilities to help emerging biotechs optimize clinical trials. The initiative aims to improve patient selection, reduce trial costs, and increase the probability of technical and regulatory success for smaller companies facing funding constraints. Early results from partnerships, such as with Sermonix, demonstrate significant reductions in enrollment startup times.GlobeNewswireSermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast CSermonix Pharmaceuticals announced publication of a Clinical Breast Cancer article on lasofoxifene's effects on vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer patients from the ELAINE-1 study. The secondary analysis showed lasofoxifene reduced symptom scores by 74-79% versus fulvestrant's increases, with a favorable safety profile. A Phase 3 trial (ELAINE-3) will further assess quality-of-life impacts.